1[1]M1iedzinska-maciejewska M,Wcislo G.Mechanism of multidrug resistance of ovarian cancer.Prxegl-Lek,2002,59: 854-858.
2[2]Nakayama K,Kanzaki A, Ogawa K, et al.Copper-transporting P-type adenosine triphosphatase as a cisplatin;comparative analysis with expression of mdr1,mrp1,mrp2,lrp and bcrp. Int J cancer,2002,101:488-495.
3[3]Nakayama K,Kanzaki A,Ogawa K, et al. ATP7B as a cisplatain based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1,MRP1,MRP2,LRP,and BCRP. Int J Cancer,2002,101: 488-495.
4[4]Holford J,Sharp SY,Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinnm complex AMD473. Br J Cancer, 1998,77:366-373.
5[5]Kawakam Y,Hama S,Hiura M, et al. Adenovirus-mediated P26 gene transfer changes the sensitivity to taxanes and vinca alkaloids of human ovarian cancer cells. Anticancer Res, 2001, 21:2537-2545.
6[6]Reles A,Wen WH,Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened surrvial in ovarian cancer. Clin Cancer Res, 2001,7:2984-2997.
7[7]Lincet H,Poulain L,Remy JS, et al. The p21 cyclin-department kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian cancer cells. Cancer Lett, 2000,161:17-26.
8[9]Stein WD. Kinetics of the multidrug transporter (P-gp)and its reversal. physid Rer,1997,77:545-590.
9[10]Frecdman DA, Levine AJ. Regulation of the p53 protein by mdm2 oncoprotein. Cancer Res, 1999,59:1-7.
10[11]Green SK,Karlsson MC,Ravetch JV, et al. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity:implications for antibody-based therapeutics of cancer. Cancer Res, 2002,62:6891-6900.
